SI2968471T1 - Peptidi za uporabo pri lokalnem zdravljenju nevrodegenerativnih bolezni mrežnice, zlasti v zgodnjih fazah diabetične retinopatije in drugih bolezni mrežnice, pri katerih igra nevrodegeneracija bistveno vlogo - Google Patents
Peptidi za uporabo pri lokalnem zdravljenju nevrodegenerativnih bolezni mrežnice, zlasti v zgodnjih fazah diabetične retinopatije in drugih bolezni mrežnice, pri katerih igra nevrodegeneracija bistveno vlogoInfo
- Publication number
- SI2968471T1 SI2968471T1 SI201430409T SI201430409T SI2968471T1 SI 2968471 T1 SI2968471 T1 SI 2968471T1 SI 201430409 T SI201430409 T SI 201430409T SI 201430409 T SI201430409 T SI 201430409T SI 2968471 T1 SI2968471 T1 SI 2968471T1
- Authority
- SI
- Slovenia
- Prior art keywords
- retinal
- diseases
- peptides
- diabetic retinopathy
- early stages
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title 2
- 206010012689 Diabetic retinopathy Diseases 0.000 title 1
- 208000017442 Retinal disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000002207 retinal effect Effects 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382063 | 2013-03-01 | ||
| EP14707980.0A EP2968471B1 (en) | 2013-03-01 | 2014-02-27 | Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role |
| PCT/EP2014/053787 WO2014131815A1 (en) | 2013-03-01 | 2014-02-27 | Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2968471T1 true SI2968471T1 (sl) | 2017-11-30 |
Family
ID=47901927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430409T SI2968471T1 (sl) | 2013-03-01 | 2014-02-27 | Peptidi za uporabo pri lokalnem zdravljenju nevrodegenerativnih bolezni mrežnice, zlasti v zgodnjih fazah diabetične retinopatije in drugih bolezni mrežnice, pri katerih igra nevrodegeneracija bistveno vlogo |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9707273B2 (enExample) |
| EP (1) | EP2968471B1 (enExample) |
| JP (2) | JP6368722B2 (enExample) |
| CN (1) | CN105007931B (enExample) |
| CA (1) | CA2901439C (enExample) |
| DK (1) | DK2968471T3 (enExample) |
| ES (1) | ES2644016T3 (enExample) |
| HR (1) | HRP20171501T1 (enExample) |
| HU (1) | HUE036542T2 (enExample) |
| MX (1) | MX364911B (enExample) |
| PL (1) | PL2968471T3 (enExample) |
| PT (1) | PT2968471T (enExample) |
| SI (1) | SI2968471T1 (enExample) |
| WO (1) | WO2014131815A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251462B2 (en) | 2013-04-23 | 2019-04-09 | Noxell Corporation | Hair consultation tool arrangement and method |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AU2016379403B2 (en) | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US10973867B2 (en) | 2015-12-30 | 2021-04-13 | Marshall University Research Corporation | Compositions and methods for treating retinopathy |
| WO2017186934A1 (en) * | 2016-04-29 | 2017-11-02 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases |
| CN106822182A (zh) * | 2016-12-27 | 2017-06-13 | 广州姿生生物科技有限公司 | 一种细胞提取物及其用途 |
| EP3443980A1 (en) * | 2017-08-15 | 2019-02-20 | Ciliocure Limited | Compound for the treatment of patients with leptin-resistant obesity, bardet-biedl syndrome and other ciliopathies |
| MX2022009136A (es) * | 2020-02-13 | 2022-08-22 | Ferrer Int | Composicion farmaceutica oftalmica y uso de la misma. |
| GB202014740D0 (en) * | 2020-09-18 | 2020-11-04 | Invex Therapeutics Ltd | Method of reducing intraocular pressure |
| US20220193201A1 (en) * | 2020-10-19 | 2022-06-23 | The Trustees Of The University Of Pennsylvania | Glp-1r agonist reduces retinal inflammation and neuron death secondary to ocular hypertension |
| IL302804A (en) * | 2020-11-09 | 2023-07-01 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Treatment of ocular diseases |
| EP4248985A1 (en) | 2022-03-25 | 2023-09-27 | Consejo Superior de Investigaciones Científicas (CSIC) | Peptides for the treatment of retinitis pigmentosa |
| KR102587729B1 (ko) * | 2023-02-27 | 2023-10-12 | 주식회사 아이바이오코리아 | 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| JP4798814B2 (ja) | 1997-01-07 | 2011-10-19 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 食物摂取低減用のエキセンジンおよびそのアゴニストの使用 |
| WO2003059373A2 (en) | 2002-01-16 | 2003-07-24 | Ramot At Tel Aviv University Ltd. | Compositions and their use for enhancing and inhibiting fertilization |
| US20120021980A1 (en) | 2004-08-25 | 2012-01-26 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| WO2007062434A2 (en) | 2005-11-22 | 2007-05-31 | Crestwave Technologies (Pty) Ltd | A mineral recovery process |
| WO2010008831A2 (en) * | 2008-06-24 | 2010-01-21 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| EP2251028A1 (en) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| ES2362604B1 (es) | 2009-12-22 | 2012-06-28 | Bcn Peptides, S.A. | Formulación tópica oftálmica de péptidos. |
| CN102643339B (zh) * | 2011-02-21 | 2014-04-09 | 天津药物研究院 | 一种glp-1类似物、制备方法及其应用 |
-
2014
- 2014-02-27 JP JP2015559495A patent/JP6368722B2/ja active Active
- 2014-02-27 PL PL14707980T patent/PL2968471T3/pl unknown
- 2014-02-27 US US14/770,067 patent/US9707273B2/en active Active
- 2014-02-27 MX MX2015011243A patent/MX364911B/es active IP Right Grant
- 2014-02-27 PT PT147079800T patent/PT2968471T/pt unknown
- 2014-02-27 DK DK14707980.0T patent/DK2968471T3/en active
- 2014-02-27 ES ES14707980.0T patent/ES2644016T3/es active Active
- 2014-02-27 EP EP14707980.0A patent/EP2968471B1/en active Active
- 2014-02-27 WO PCT/EP2014/053787 patent/WO2014131815A1/en not_active Ceased
- 2014-02-27 CA CA2901439A patent/CA2901439C/en active Active
- 2014-02-27 SI SI201430409T patent/SI2968471T1/sl unknown
- 2014-02-27 CN CN201480009196.9A patent/CN105007931B/zh active Active
- 2014-02-27 HU HUE14707980A patent/HUE036542T2/hu unknown
- 2014-02-27 HR HRP20171501TT patent/HRP20171501T1/hr unknown
-
2018
- 2018-02-21 JP JP2018029089A patent/JP2018111702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014131815A1 (en) | 2014-09-04 |
| EP2968471A1 (en) | 2016-01-20 |
| HRP20171501T1 (hr) | 2017-11-17 |
| CA2901439A1 (en) | 2014-09-04 |
| BR112015020143A2 (pt) | 2017-08-29 |
| MX364911B (es) | 2019-05-13 |
| US20160000882A1 (en) | 2016-01-07 |
| PL2968471T3 (pl) | 2017-12-29 |
| CN105007931B (zh) | 2018-04-06 |
| JP2016510728A (ja) | 2016-04-11 |
| US9707273B2 (en) | 2017-07-18 |
| PT2968471T (pt) | 2017-10-24 |
| JP6368722B2 (ja) | 2018-08-01 |
| JP2018111702A (ja) | 2018-07-19 |
| CA2901439C (en) | 2023-04-04 |
| HUE036542T2 (hu) | 2018-07-30 |
| EP2968471B1 (en) | 2017-07-19 |
| CN105007931A (zh) | 2015-10-28 |
| DK2968471T3 (en) | 2017-10-23 |
| MX2015011243A (es) | 2016-04-25 |
| ES2644016T3 (es) | 2017-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE036542T2 (hu) | Peptidek retina neurodegeneratív betegségének topikális kezelésében történõ alkalmazásra, különösen diabeteszes retinopátia korai szakaszaiban és más olyan retinabetegségekben, amelyekben a neurodegeneráció lényeges szerepet játszik | |
| IL267997A (en) | Preparations, formulations and methods for treating eye diseases | |
| ZA201408592B (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| EP2991670B8 (en) | Sobetirome in the treatment of myelination diseases | |
| IL239735A0 (en) | Treatment and diseases associated with toxic aldehyde | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| HK1218621A1 (zh) | 用於治疗慢性炎症和炎性疾病的组合物及方法 | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| LT3292875T (lt) | Kompozicijos ir būdai, skirti ligų gydymui | |
| EP3238736A4 (en) | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same | |
| IL239629B (en) | History of benzylideneguanidine and therapeutic use for the treatment of diseases resulting from misfolding of proteins | |
| EP3318879A4 (en) | Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag | |
| EP3131524A4 (en) | Methods and compositions for topical delivery for skin care | |
| LTPA2020511I1 (lt) | Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui | |
| IL245738A0 (en) | Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases | |
| EP3019138A4 (en) | Guiding means for administering acupuncture and other healing procedures | |
| EP2990040A4 (en) | Therapeutic agent for eyeground disease | |
| PT3021881T (pt) | Ácido hialurónico reticulado, processo para a sua preparação e sua utilização no campo da estética | |
| EP3075380A4 (en) | Drug for treating vertebrae cervicales and lumber diseases | |
| EP2969008A4 (en) | MEDICATION FOR THE TREATMENT OF CANCER, CARDIOVASCULAR DISEASES AND INFLAMMATION | |
| PH12017501979A1 (en) | Pharmaceutical compound | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| EP2988737A4 (en) | Methods and compositions for treating diseases | |
| TH1401006421A (th) | สารประกอบสำหรับการใช้ในการผลิตยาสำหรับการรักษาโรคผิวหนังที่ตอบสนองต่อสเตียรอยด์ | |
| HK1230581A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases |